Current management - Management of rheumatic diseases in the era of biological anti-rheumatic drugs

被引：10

作者：

Konttinen, YT ^{[1
]}

Seitsalo, S

Lehto, M

Santavirta, S

机构：

[1] Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland

[2] ORTON Orthopaed Hosp Invalid Fdn, Helsinki, Finland

[3] Hosp Joint Replacement, COXA, Tampere, Finland

[4] Univ Helsinki, Cent Hosp, Dept Orthopaed & Traumatol, Helsinki, Finland

来源：

ACTA ORTHOPAEDICA | 2005年 / 76卷 / 05期

关键词：

D O I：

10.1080/17453670510041673

中图分类号：

R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学（修复外科学）];

学科分类号：

摘要：

[No abstract available]

引用

页码：614 / 619

页数：6

共 12 条

[1] A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate [J].

Cohen, SB ;

Moreland, LW ;

Cush, JJ ;

Greenwald, MW ;

Block, S ;

Shergy, WJ ;

Hanrahan, PS ;

Khraishi, MM ;

Patel, A ;

Sun, G ;

Bear, MB .

ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 (09) :1062-1068

[2] Frequency of infection in patients with rheumatoid arthritis compared with controls - A population-based study [J].

Doran, MF ;

Crowson, CS ;

Pond, GR ;

O'Fallon, WM ;

Gabriel, SE .

ARTHRITIS AND RHEUMATISM, 2002, 46 (09) :2287-2293

[3] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis [J].

Edwards, JCW ;

Szczepanski, L ;

Szechinski, J ;

Filipowicz-Sosnowska, A ;

Emery, P ;

Close, DR ;

Stevens, RM ;

Shaw, T .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) :2572-2581

[4] Tuberculosis associated with infliximab, a tumor necrosis factor (alpha)-neutralizing agent [J].

Keane, J ;

Gershon, S ;

Wise, RP ;

Mirabile-Levens, E ;

Kasznica, J ;

Schwieterman, WD ;

Siegel, JN ;

Braun, MM .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (15) :1098-1104

[5] Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy - A randomized, placebo-controlled, 52-week trial [J].

Keystone, EC ;

Kavanaugh, AF ;

Sharp, JT ;

Tannenbaum, H ;

Hua, Y ;

Teoh, LS ;

Fischkoff, SA ;

Chartash, EK .

ARTHRITIS AND RHEUMATISM, 2004, 50 (05) :1400-1411

[6] Infliximab and methotrexate in the treatment of rheumatoid arthritis [J].

Lipsky, PE ;

van der Heijde, DMFM ;

St Clair, EW ;

Furst, DE ;

Breedveld, FC ;

Kalden, JR ;

Smolen, JS ;

Weisman, M ;

Emery, P ;

Feldmann, M ;

Harriman, GR ;

Maini, RN .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1594-1602

[7] Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:: a randomised phase III trial [J].

Maini, R ;

St Clair, EW ;

Breedveld, F ;

Furst, D ;

Kalden, J ;

Weisman, M ;

Smolen, J ;

Emery, P ;

Harriman, G ;

Feldmann, M ;

Lipsky, P .

LANCET, 1999, 354 (9194) :1932-1939

[8] Etanercept therapy in rheumatoid arthritis - A randomized, controlled trial [J].

Moreland, LW ;

Schiff, MH ;

Baumgartner, SW ;

Tindall, EA ;

Fleischmann, RM ;

Bulpitt, KJ ;

Weaver, AL ;

Keystone, EC ;

Furst, DE ;

Mease, PJ ;

Ruderman, EM ;

Horwitz, DA ;

Arkfeld, DG ;

Garrison, L ;

Burge, DJ ;

Blosch, CM ;

Lange, MLM ;

McDonnell, ND ;

Weinblatt, ME .

ANNALS OF INTERNAL MEDICINE, 1999, 130 (06) :478-+

[9] Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [J].

Moreland, LW ;

Baumgartner, SW ;

Schiff, MH ;

Tindall, EA ;

Fleischmann, RM ;

Weaver, AL ;

Ettlinger, RE ;

Cohen, S ;

Koopman, WJ ;

Mohler, K ;

Widmer, MB ;

Blosch, CM .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :141-147

[10]

NORSTROM DC, IN PRESS RHEUMATOL I

← 1 2 →